Biocon shares dip 1% after FDA inspection issues
pre-market1 source ↓written by the desknot a recommendation
- Biocon's stock fell
- 1%
- after the FDA
- 30 Apr 2026
Biocon's stock fell 1% on 30 Apr 2026 after the FDA identified five issues at its Bengaluru biosimilars facility during an inspection. The company asserts these are procedural and pose no risk to data integrity. Meanwhile, Biocon secured Health Canada approvals for two denosumab biosimilars, maintaining momentum in the global market.
Not investment advice. For informational purposes only.